Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
- None.
- None.
Three batches tested and validated by third-party laboratory
VANCOUVER, British Columbia, April 15, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence.
As previously communicated in January, Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process. The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel.
Bill Ciprick, CEO of Optimi, confirms that the MDMA was tested and validated by a third-party laboratory, therefore meeting the Company’s quality assurance standards.
“The ability to receive an order, make the API, test the MDMA, and validate the results is a testament to the capabilities we have when working with clients,” said Ciprick. “This clearly highlight’s Optimi's achievements in MDMA API production and conveys the Company's strengths in manufacturing, testing, and client collaboration on an international scale.”
He emphasized the Company's distinctive advantage with in-house production as a key differentiator in providing the highest quality products at the most competitive prices in the market. "To excel in this industry, we must fully understand every aspect of product creation. The more we engage in it, the more proficient we become in refining our expertise, thereby reducing time and resource consumption. Ultimately, this leads to cost savings that we can extend to our clients."
Bryan Safarik, Optimi's Chief Operations Officer, affirms that over three batches, the Company was able to manufacture more than 60 grams of MDMA API, highlighting Optimi's capability for on-demand manufacturing.
"I'm pleased to report that the produced MDMA API is securely stored in the Company's Level 8 Security vault until the requisite permits are secured from Health Canada for contract fulfillment and export to Israel," he remarked. "This achievement owes much credit to our dedicated science and quality teams for their diligent efforts."
Optimi’s in-house MDMA manufacturing and encapsulation expertise can viewed on the Company’s YouTube page by clicking here.
4th Annual Psychedelic Therapeutics and Drug Development Conference:
Optimi’s world-class psychedelic manufacturing operations will be on full display this May at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston (May 23-24). Bill Ciprick will deliver a presentation on Thursday, May 23, 2024, at 10:40 a.m. EST. His session, titled “Manufacturing the Future of GMP Psychedelics: What Researchers, Clinicians, and Drug Developers Need to Know,” promises to provide invaluable insights into the evolving landscape of Good Manufacturing Practice (GMP) psychedelic drugs.
For media inquiries, please contact Michael Kydd:
michaelk@optimihealth.ca
902.880.6121
For investor inquiries, please contact:
investors@optimihealth.ca
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN):
Optimi Health Corp. is a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug candidates throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
FORWARD‐LOOKING STATEMENTS:
This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. forward-looking statements made in this news release include the proposed use of the proceeds of the Offering. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.
Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.
FAQ
What milestone did Optimi Health achieve?
How many batches of MDMA API were tested and validated?
Who confirmed the testing and validation of the MDMA API?
How much MDMA API was produced over three batches?
Where is the produced MDMA API stored?
What will be showcased at the 4th Annual Psychedelic Therapeutics and Drug Development Conference?
Who will deliver a presentation at the conference?
What is the title of Bill Ciprick's session at the conference?
How can Optimi's in-house MDMA manufacturing and encapsulation expertise be viewed?
Who can be contacted for media inquiries?
Who can be contacted for investor inquiries?
